Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
45 hedge funds and large institutions have $26.6M invested in Cidara Therapeutics in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 10 closing their positions.
0.09% more ownership
Funds ownership: 2.89% → 2.97% (+0.09%)
8% less funds holding
Funds holding: 49 → 45 (-4)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less capital invested
Capital invested by funds: $42.5M → $26.6M (-$16M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$4.77M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$1.96M |
| 3 |
Renaissance Technologies
New York
|
+$445K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$288K |
| 5 |
DMK
David M. Knott
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.65M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$517K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$257K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$254K |
| 5 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$249K |
CDTX Hedge Fund Activity: Q2 2019 in Review
45 of the 4,624 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2019, worth a combined $26.6M — down 38% from $42.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CDTX and 8 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 8 added.
The largest buyer was Bellevue Group, opening a new position worth an estimated $4.77M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.65M sold.
- 45 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2019, down from 49 in Q1 2019.
- Funds reported $26.6M of Cidara Therapeutics stock for Q2 2019, down 38% quarter-over-quarter.
- 8 funds opened new Cidara Therapeutics positions in Q2 2019 and 10 closed out, a net change of -2 holders.
- The largest Cidara Therapeutics buyer in Q2 2019 was Bellevue Group, an estimated $4.77M added.
- The largest Cidara Therapeutics seller in Q2 2019 was Opaleye Management, an estimated $2.65M sold.
Based on aggregated 13F filings for Q2 2019.